Schatzberg's Manual of Clinical Psychopharmacology by Alan F. Schatzberg (Englis
168,07 €
By Alan F. Schatzberg, Charles DeBattista. To ensure that the ever-expanding number of available agents with widening indications receives proper coverage, the authors have continued their effort to cull or condense coverage of less commonly used agents (e.g., barbiturates) in favor of more recently approved drugs (e.g., VMAT-2 inhibitors for tardive dyskinesia, pimavanserin) and those whose approval by the U.S. Food and Drug Administration (FDA) appears imminent.
Jetzt bei Ebay: